Concerted effect of transforming growth factor-β, cyclin inhibitor p21, and c-myc on smooth muscle cell proliferation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 3 55-3, 2004, Pages

  Khanna, Ashwani ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Antisense oligonucleotide; Antisense plasmid DNA; Atherosclerosis; Cancer; Gene overexpression; Reverse transcriptase polymerase chain reaction

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MYC PROTEIN; PLASMID DNA; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ATHEROSCLEROSIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 1342283050     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00462.2003     Document Type: Article

References (63)

1. 2+ ATPase-4 in the vascular smooth muscle cell cycle. Am J Physiol Cell Physiol 285: C88-C95, 2003.
2. Amati B. Integrating Myc and TGF-β signalling in cell-cycle control. Nat Cell Biol 3: E112-E113, 2001.
3. Bennett MR, Littlewood TD, Hancock DC, Evan GI, and Newby AC. Down-regulation of the c-myc proto-oncogene in inhibition of vascular smooth-muscle cell proliferation: a signal for growth arrest? Biochem J 302: 701-708, 1994.
4. Bernard O, Cory S, Gerondakis S, Webb E, and Adams JM. Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours. EMBO J 2: 2375-2383, 1983.
5. Bochaton-Piallat ML, Ropraz P, Gabbiani F, and Gabbiani G. Phenotypic heterogeneity of rat arterial smooth muscle cell clones: implications for the development of experimental intimal thickening. Arterioscler Thromb Vasc Biol 16: 815-820, 1996.
6. 2+-calcineurin-mediated activation in thymocytes. J Immunol 170: 3645-3652, 2003.
7. Bouchard C, Staller P, and Eilers M. Control of cell proliferation by Myc. Trends Cell Biol 8: 202-206, 1998.
8. Chang MW, Barr E, Lu MM, Barton K, and Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 96: 2260-2268, 1995.
9. Chen CR, Kang Y, Siegel PM, and Massague J. E2F4/5 and p107 as Smad cofactors linking the TGF-β receptor to c-myc repression. Cell 110: 19-32, 2002.
10. Chen D, Guo K, Yang J, Frazier WA, Isner JM, and Andres V. Vascular smooth muscle cell growth arrest on blockade of thrombospondin-1 requires p21(Cip1/WAF1). Am J Physiol Heart Circ Physiol 277: H1100-H1106, 1999.
11. Chen HW and Huang HC. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 124: 1029-1040, 1998.
12. Claassen GF and Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor β-induced cell-cycle arrest. Proc Natl Acad Sci USA 97: 9498-9503, 2000.
13. Condorelli G, Aycock JK, Frati G, and Napoli C. p21 Transgene overexpression induces a significant reduction of restenosis in hypercholesterolemic apolipoprotein E knockout mice subjected to injury of common carotid artery. FASEB J 15: 2162-2170, 2001.
14. Datto MB, Yu Y, and Wang XP. Functional analysis of the transforming growth factor-β responsive elements in the WAF/Cip1/p21 promoter. J Biol Chem 270: 28623-28628, 1995.
15. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, and Marks JR. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5: 1301-1307, 1994.
16. Fukui R, Shibata N, Kohbayashi E, Amakawa M, Furutama D, Hoshiga M, Negoro N, Nakakouji T, Ii M, Ishihara T, and Ohsawa N. Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1). Atherosclerosis 11: 53-59, 1997.
17. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe J, Carter ND, and Spector TD. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 8: 93-97, 1999.
18. Grainger DJ and Metcalfe JC. Transforming growth factor-β: the key to understanding lipoprotein(a)? Curr Opin Lipidol 6: 81-85, 1995.
19. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, and Metcalfe JC. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1: 74-79, 1995.
20. Greiber S, Kramer-Guth A, Pavenstadt H, Gutenkunst M, Schollmeyer P, and Wanner C. Effects of lipoprotein(a) on mesangial cell proliferation and viability. Nephrol Dial Transplant 11: 778-785, 1996.
21. Gunn J, Holt CM, Francis SE, Shepherd L, Grohmann M, Newman CM, Crossman DC, and Cumberland DC. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res 80: 520-31, 1997.
22. Halloran BG, Prorok GD, So BJ, and Baxter BT. Transforming growth factor-β1 inhibits human arterial smooth-muscle cell proliferation in a growth-rate-dependent manner. Am J Surg 170: 193-197, 1995.
23. Hao H, Gabbiani G, and Bochaton-Pialla M. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 23: 1510-1520, 2003.
24. Ihling C, Menzel G, Wellens E, Monting JS, Schaefer HE, and Zeiher AM. Topographical association between the cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arterioscler Thromb Vasc Biol 17: 2218-2224, 1997.
25. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ, and Fontana JA. p21/waf1/cip1 and mdm-2 expression in breast cancer carcinoma patients as related to prognosis. Int J Cancer 74: 529-534, 1997.
26. Kanse SM, Benzakour O, Kanthou C, Kost C, Lijnen HR, and Preissner KT. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol 17: 2848-2854, 1997.
27. Kanwar RK, Kanwar JR, Wang D, Ormrod DJ, and Krissansen GW. Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 21: 1991-1997, 2001.
28. Khanna A, Cairns V, and Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-β in lymphoid and non-lymphoid cells. Transplantation 67: 614-619, 1999.
29. Khanna A and Hosenpud J. CsA induces the expression of the cyclin inhibitor p21. Transplantation 67: 1262-1268, 1999.
30. Khanna AK and Hosenpud JD. In vitro and in vivo transfection of p21 gene enhances cyclosporin A-mediated inhibition of lymphocyte proliferation. J Immunol 165: 1882-1888, 2000.
31. Khanna A, Li B, Li P, and Suthanthiran M. Transforming growth factor-β1: regulation with a TGF-β1 antisense oligomer. Kidney Int Suppl 53: S2-S6, 1996.
32. Kipshidze N, Keane E, Stein D, Chawla P, Skrinska V, Shankar LR, Khanna A, Komorowski R, Haudenschild C, Iversen P, Leon MB, Keelan MH, and Moses J. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv 54: 247-256, 2000.
33. Leng L, Du B, Consigli S, and McCaffrey TA. Translocation of protein kinase C-δ by PDGF in cultured vascular smooth muscle cells: inhibition by TGF-β1. Artery 22: 140-154, 1996.
34. Li CY, Suardet L, and Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J Biol Chem 270: 4971-4974, 1995.
35. 2+ ATPase regulation. J Biol Chem 271: 27788-27794, 1996.
36. Malliri A, Yeudall WA, Nikolic M, Crouch DH, Parkinson EK, and Ozanne B. Sensitivity to transforming growth factor β1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21 induction are important early events. Cell Growth Differ 7: 1291-1304, 1996.
37. Markowitz SD. Atherosclerosis, just another cancer? J Clin Invest 100: 2143-2145, 1997.
38. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, and Bush HL Jr. Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β1. J Clin Invest 96: 2667-2675, 1995.
39. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanborn TA, Bergman G, and Bush HL Jr. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 100: 2182-2188, 1997.
40. McCaffrey TA, Du B, Fu C, Bray PJ, Sanborn TA, Deutsch E, Tarazona N, Shaknovitch A, Newman G, Patterson C, and Bush HL Jr. The expression of TGF-β receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 31: 1627-1642, 1999.
41. McCaffrey TA and Falcone DJ. Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-β in vascular smooth muscle cells. Mol Biol Cell 4: 315-322, 1993.
42. Metcalfe JC and Grainger DJ. Transforming growth factor-β and the protection from cardiovascular injury hypothesis. Biochem Soc Trans 23: 403-406, 1995.
43. Metcalfe JC and Grainger DJ. A pivotal role for TGF-β in atherogenesis? Biol Rev Camb Philos Soc 70: 571-596, 1995.
44. Metzler B, Abia R, Ahmad M, Wernig F, Pachinger O, Hu Y, and Xu Q. Activation of heat shock transcription factor 1 in atherosclerosis. Am J Pathol 16: 1669-1676, 2003.
45. Mii S, Ware JA, and Kent KC. Transforming growth factor-β inhibits human smooth muscle cell growth and migration. Surgery 114: 464-470, 1993.
46. 1 receptor mRNA by calreticulin. Circ Res 90: 53-58, 2002.
47. Ohkawa Y, Hayashi K, and Sobue K. Calcineurin-mediated pathway involved in the differentiated phenotype of smooth muscle cells. Biochem Biophys Res Commun 301: 78-83, 2003.
48. Opas M, Dziak E, Fliegel L, and Michalak M. Regulation of expression and intracellular distribution of calreticulin, a major calcium binding protein of nonmuscle cells. J Cell Physiol 149: 160-171, 1991.
49. Patton WF, Erdjument-Bromage H, Marks AR, Tempst P, Taubman MB, Villaschi S, Nicosia RF, and Smith MR. Isolation of a morphologically and functionally distinct smooth muscle cell type from the intimal aspect of the normal rat aorta; evidence for smooth muscle cell heterogeneity. In Vitro Cell Dev Biol Anim 30A: 589-595, 1994.
50. Patton WF, Erdjument-Bromage H, Marks AR, Tempst P, and Taubman MB. Components of the protein synthesis and folding machinery are induced in vascular smooth muscle cells by hypertrophic and hyperplastic agents. Identification by comparative protein phenotyping and microsequencing. J Biol Chem 270: 21404-21410, 1995.
51. Rao GN, Alexander RW, and Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 96: 842-847, 1995.
52. Roma P and Catapano AL. Stress proteins and atherosclerosis. Atherosclerosis 127: 147-154, 1996.
53. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, and Ginsburg GS. Atherosclerosis: a cancer of the blood vessels? Am J Clin Pathol 116, Suppl: S97-S107, 2001.
54. Ross R. The pathogenesis of atherosclerosis: a prospective for the 1990s. Nature 362: 801-809, 1993.
55. Sanders M. Molecular and cellular concepts in atherosclerosis. Pharmacol Ther 61: 109-153, 1994.
56. Satterwhite DJ and Moses HL. Mechanism of transforming growth factor-β1-induced cell cycle arrest. Invasion Metastasis 14: 309-318, 1994.
57. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, and Lodish HF. A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma. Blood 94: 2854-2861, 1999.
58. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, and Nerem RM. The pathogenesis of atherosclerosis: an overview. Clin Cardiol 14, Suppl 1: I1-I16, 1991.
59. Weston K. Myb proteins in life, death and differentiation. Curr Opin Genet Dev 8: 76-81, 1998.
60. Wilson E, Sudhir K, and Ives HE. Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions. J Clin Invest 96: 2364-2372, 1995.
61. Wu S, Theodorescu D, Kerbel RS, Wilson JKB, Mulder KM, Humphrey LS, and Brattain MG. TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 116: 187-196, 1992.
62. Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, Miyazono K, Kato M. c-myc is a downstream target of the Smad pathway. J Biol Chem 277: 854-861, 2002.
63. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, and Nabel EG. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci USA 93: 7905-7910, 1996.